. Author manuscript; available in PMC: 2016 Jan 5.

Published in final edited form as: Nat Rev Clin Oncol. 2014 Sep 30;11(11):637–648. doi: 10.1038/nrclinonc.2014.159

Table 2.

Radionucleotide immunoconjugates

Agent	Diseases treated	Radionucleotide	Linker	Antibody type	Developmental stage
Ibritumomab tiuxetan^88,89	Relapsed/refractory B-cell non-Hodgkin lymphoma	Yttrium-90 or Indium-111	Not cleaved	Mouse monoclonal IgG1 targeting CD20	FDA approved in 2002

Iodine tositumomab^92,93	Follicular lymphoma	Iodine-131	Not cleaved	Mouse monoclonal IgG2 targeting CD20	FDA approved in 2003 Discontinued by manufacturer in 2014

90Y-DOTA-biotin with NR-LU-10 pretargeting antibody¹⁰⁰	Colorectal cancer	Yttrium-90	NA	Mouse monoclonal IgG2 targeting Ep-CAM (expressed by epithelial tumours)	Proof of concept, proved too toxic and ineffective

Targeted α-therapy^99,100	NA	α-Particle	NA	NA	In preclinical development

Abbreviation: NA, not applicable.